The Atlas

GLP-1s & metabolic therapies

The retatrutide kidney registry now adds a null 24-week measured-GFR primary comparison alongside a small albuminuria signal. New oral-ecnoglutide and mazdutide type 1 diabetes protocols have no results. Trial population, formulation, analysis and safety remain separate; the October head-to-head diabetes result is retained.

Cardiovascular prevention

Novartis has discontinued pelacarsen’s ASCVD program; the safety extension now records termination. HORIZON and ZEUS lowered biomarkers without demonstrated cardiovascular-event benefit in their studied secondary-prevention populations. VERVE-102 HEART-3 now lists recruiting, with an actual September start and no results.

Kidney health

Retatrutide’s short CKD study did not improve its measured-GFR primary comparison; a much smaller albuminuria analysis favored treatment, with endpoint-specific denominators and harms. MZE829’s separate APOL1-kidney HORIZON study completes enrollment, with early 2027 data forecast. Neither demonstrates prevention of kidney failure.

Liver health

The small CIDEB-siRNA report adds sustained 36-week liver-fat reductions, with no demonstrated histologic fibrosis reversal or fewer clinical liver events. Earlier abstracts and current analysis populations differ and remain explicitly unharmonized. Viral-hepatitis findings are cross-linked separately.

Longevity & healthspan

VITAL-H’s registered functional-healthspan protocol remains without results. A newly recovered sponsor first-dose report for SenoMune concerns advanced cancer and lacks a verified public protocol/oversight; it is not healthy-adult longevity evidence. Biomarker and animal results remain separate from human healthspan benefit.

Cancer treatment & vaccines

PIKTOR plus paclitaxel shows uncontrolled responses in selected previously treated endometrial cancers, with grade ≥3 treatment-related harms in 64%. New EGFR-ADC/checkpoint Phase 3 protocols address distinct esophageal and nasopharyngeal settings. No new comparative survival benefit or U.S. approval follows from these reports.

Cancer blood tests & screening

A new self-sampling delivery trial will measure screening completion and diagnostic resolution; a recovered portable-ultrasound study concerns abnormal breast examinations, not replacement of population mammography. Galleri’s early Q1 2027 FDA-decision forecast remains sponsor timing, with no new approval established.

Genetic screening & risk

BRIDGES-NBS moves toward Oregon enrollment according to its laboratory partner, while Minnesota’s exact start remains planned. Feasibility, additional diagnoses and changes in management remain distinct from long-term clinical benefit; no prospective benefit from polygenic embryo selection is established.

Whole-body MRI

A new review of heterogeneous screening cohorts estimates pathology-confirmed cancer yield but cannot establish improved patient outcomes. Downstream workups, false positives, overdiagnosis and the benefit of repeated screening remain unresolved.

Mental-health treatments

The second lumateperone trial reports improved acute bipolar I mania symptoms; a U.S. mania indication is still investigational. Brenipatide adds a Phase 2 adjunctive-depression protocol, with no outcomes. Neither is a new SSRI; psychedelic research remains separate.

Psilocybin & related therapies

Compass has completed the COMP360 NDA for treatment-resistant depression; acceptance, approval and access remain separate. The Usona MDD filing report is still unconfirmed. Small new MDMA and R(-)-MDMA studies address different populations and do not establish broad efficacy or long-term safety.

Alzheimer’s

TARBELA-AD now lists recruitment for an oral NLRP3 inhibitor, RG6434/RO7568282, with clinical outcomes planned. CTAD will present early safety, trontinemab biomarker data and PrevenTRON design; these are separate from demonstrated cognitive or prevention benefit. Prior negative AuTonomy and sabirnetug findings remain relevant.

Hearing & vision

ReBUILD adds a topical bevemipretide Phase 2/3 protocol for dry AMD, with a structural primary endpoint. Inherited BEST1 research remains separate. AC102’s sudden-hearing-loss study is complete without posted outcomes; the reported 2027 plans remain unconfirmed.

Insomnia

Daridorexant has a sponsor-reported pediatric breakthrough designation; approval is still limited to adult insomnia. DARI-DREAM has begun recruiting for a distinct adult study. Guided digital CBT-I results and the SOM001 and CBD programs remain separate; no new durable architecture or safety conclusions follow.

Obstructive sleep apnea

Monthly berobenatide’s non-PAP VESPER-OSA2 trial now lists recruitment without results. Existing LunAIRo tables clarify AD109 efficacy and harms; study withdrawal and drug discontinuation differ. AD109’s FDA action target remains February 28, 2027, with no approval inferred.

Narcolepsy & excessive sleepiness

DEA’s oveporexton Schedule IV rule is scheduled to publish and become effective November 12. Existing U.S. adult narcolepsy type 1 approval, actual U.S. launch and insurer coverage are separate. Japan and China launches were previously announced.

Circadian rhythm disorders

The tasimelteon jet-lag hearing now has a December 14–18 schedule. A hearing is not approval; existing circadian-disorder indications and the proposed new use remain separate.

Restless legs syndrome

Newly recovered IV-iron and extended-duration TOMAC programs target refractory RLS and awakenings. An uncontrolled venous-ablation association does not establish a general RLS cure or causal benefit.

Bones, joints & cartilage

ACR abstracts quantify retatrutide knee-pain improvements under efficacy estimands; they do not establish cartilage regeneration. A local-iloprost fracture-healing trial is newly registered. NVD003’s large completion-estimate change needs explanation; TG-C December timing remains unconfirmed.

Muscle preservation

A scheduled enobosarm post-hoc function report and new COMPACT supportive-care trial keep functional outcomes separate from tissue preservation. Isembyld first U.S. infusions are now sponsor-confirmed for October; SRK-439 public data are forecast Q1 2027, not a new efficacy result.

Non-opioid pain

Alenura reports a positive acute bladder-pain Phase2 topline without effect magnitude or comparative harms. A new suzetrigine knee-replacement pilot prioritizes feasibility. Chronic neuropathy benefit remains unproven; HNK is still not yet recruiting.

Autoimmune therapies

Early ALLO-329 and NKX019 cohorts show disease-specific activity with important conditioning and denominator limits. KYSA-8’s full paper adds serious harms and a reporting discrepancy to the same SPS cohort. TOGETHER-PsA week52 uncertainty is now available, but exploratory methods and incomplete harms remain.

Allergy & airway disease

Newly tracked WIN378 is testing longer-interval TSLP blockade in asthma and COPD. Early lung-function and biomarker signals do not establish fewer severe exacerbations or long-term safety. Registry and sponsor descriptions differ on phase and enrollment.

Infections, vaccines & antibiotics

ECLIPSE 1 reports strong hepatitis-delta virologic suppression using its prespecified week-48 versus delayed-treatment week-12 comparison. Selected SOLSTICE withdrawal and HBV gene-editing biomarkers do not establish cure. A Shigella challenge topline lacks effect magnitude; recovered antibiotic-conjugate evidence documents infusion reactions and stopped development.

Skin aging & laxity

A randomized skin-quality injection study reports short-term appearance benefit versus no treatment. New toxin-combination and tiny reversal protocols broaden the pipeline without results; reversal timing and U.S. regulatory forecasts remain uncertain.

Acne & rosacea

Late-posted BMX-010 rosacea observations involve only six uncontrolled participants and cannot establish efficacy. A new acne protocol keeps the retinoid background identical. Denifanstat Phase 3 topline remains forecast for H2 2027.

Pigmentation & skin tone

A newly registered GR2301 anti-IL-15 Phase 2 study adds to the vitiligo pipeline, without outcomes. Existing povorcitinib results and safety findings remain relevant; repigmentation thresholds do not establish cure or long-term safety.

Scars & stretch marks

SNT-9465 recruitment is paused after local skin irritation; an unblinded review is expected in Q4 2026 before restart or discontinuation is decided. This makes the earlier topline forecast conditional. Other scar programs remain investigational.

Hair loss & graying

VDPHL01 has sponsor-reported 12-month hair gains, but placebo participants crossed to active treatment after month six. No superiority to standard minoxidil is established. New historical N1087 entries broaden the formal oral-minoxidil watch; hair-pigment programs remain separate.

Facial volume & contour

Two uncontrolled GLP-1 cohorts report improved facial satisfaction after aesthetic treatment; they do not demonstrate fat regeneration. A randomized temple-PLLA study adds controlled six-month appearance evidence for a specific formulation, with local reactions and limited comparative durability.

Fat removal & cellulite

CBL-514 has sponsor-reported clearance for a small Chinese pharmacokinetic/safety study, with enrollment forecast for December. This is separate from SUPREME Phase 3 efficacy research and supplies no marketing approval or new visceral-fat result.

Dental alignment & regeneration

A sham-controlled laser study reports short-term pain relief but no root protection or faster alignment. A late-registered printed-aligner study tests material changes after human wear, not tooth movement or retention. Broader regenerative and orthodontic programs remain under watch.